Vaccine Communication: Another Opportunity for Biopharma to Lead
We’ve all seen this movie, right? It feels like we’re in the fake final scene before the jump-scare and the bad guy makes one final... Read More
Your Edge In Biotech.
About Kyle Serikawa
Kyle Serikawa received his PhD in Genetics from the University of California at Berkeley in 1996 and moved to Seattle to pursue postdoctoral research positions in algal development and the cell cycle of yeast. He was an early adopter of microarrays as tools for the genome-wide measurement of transcription in cells and tissues.
After a stint as a lab manager for a microarray facility, Kyle moved to Rosetta Inpharmatics, a subsidiary of Merck Pharmaceuticals where he managed projects to implement whole genome single nucleotide polymorphism genotyping as an assay tool for Merck scientists, as well as investigating new technologies in biomarker identification and validation. He also developed methods for analyzing limited amounts of nucleic acids. He moved to Novo Nordisk in 1999 to apply his skills in next-generation sequencing, qRT-PCR, and genetic analysis to the problem of finding new targets and biomarkers in the therapeutic areas of Lupus, Rheumatoid Arthritis and Inflammatory Bowel Disease.
Kyle has also worked as a project manager for a Type 1 Diabetes biobank at the Benaroya Research Institute and currently does work as a product scientist, project manager and consultant in the Seattle area. His interests span biopharma, organizational effectiveness, baseball, patient engagement, health politics and information technology.
Latest Contributions
Facing the Consequences of a Misinformation Pandemic
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward... Read More
Baseball Comes to Surprise Medical Billing
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward... Read More
LivLyme and the Many Hats of Patient Advocacy Organizations
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward... Read More
23andMe, the Burden of Knowledge, and the Real Value of Money
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward... Read More
So You Want To Get Into Biotech…Part 2: Banana Peel? What Banana Peel?
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward... Read More
So You Want To Get Into Biotech…Part 1: Many Stories, Many Paths
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward... Read More
Start of a Drug: Square Pegs, Round Indications (part 3 of 3)
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward... Read More